Skip to content
Evigrade
CriticalDirect thrombin inhibitor×Antifungal, triazole

Updated · Methodology

Mechanism

Dabigatran etexilate is a substrate of the efflux transporter P-glycoprotein (P-gp), so P-gp inhibitors raise dabigatran plasma levels (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Itraconazole strongly inhibits CYP3A4 and also inhibits P-gp (itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The pair has not been studied together, but in vitro data predict an effect similar to that of ketoconazole. Ketoconazole 400 mg raised the dabigatran area under the curve (AUC) 2.38–2.53-fold and peak concentration 2.35–2.49-fold (dabigatran SmPC, EMA). Strong P-gp inhibitors are among the main factors that raise dabigatran levels and the risk of bleeding (dabigatran SmPC, EMA). After itraconazole is stopped, its levels fall to almost undetectable within 7–14 days, and the fall can be even slower in liver cirrhosis (itraconazole SmPC, AEMPS).

Symptoms

The main risk is bleeding, overt or occult, in any tissue or organ, and it can be fatal (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Bleeding may be gastrointestinal, rectal or haemorrhoidal, from the nose, in the urine, into the skin or as bruising, or intracranial (dabigatran SmPC, EMA). Occult bleeding shows as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or unexplained shock (dabigatran SmPC, EMA). An unexplained drop in haemoglobin, haematocrit or blood pressure points to bleeding (dabigatran SmPC, EMA).

Management

The combination is contraindicated in the SmPCs of both drugs. The dabigatran summary of product characteristics (SmPC) contraindicates strong P-glycoprotein (P-gp) inhibitors and names itraconazole among them (dabigatran SmPC, European Medicines Agency, EMA). The itraconazole SmPC lists dabigatran among contraindicated drugs (itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Do not give dabigatran during itraconazole treatment or for 2 weeks after it ends (itraconazole SmPC, AEMPS). During dabigatran treatment, watch for signs of bleeding or anaemia, especially when several risk factors combine (dabigatran SmPC, EMA). If haemoglobin, haematocrit or blood pressure fall without explanation, look for the bleeding site (dabigatran SmPC, EMA). In severe bleeding, stop dabigatran and investigate the cause (dabigatran SmPC, EMA). For adults with life-threatening or uncontrolled bleeding, the specific reversal agent idarucizumab is available (dabigatran SmPC, EMA). US labels are softer. The US Food and Drug Administration (FDA) itraconazole label does not contraindicate the pair: monitor for adverse reactions and lower the dabigatran dose if needed (itraconazole label, FDA). The dabigatran FDA label says to avoid P-gp inhibitors at creatinine clearance below 50 mL/min when dabigatran treats or prevents deep vein thrombosis and pulmonary embolism, and at 15–30 mL/min when it prevents stroke in atrial fibrillation (dabigatran FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dabigatran

Other interactions with Itraconazole